Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
19GBD6T9L7
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
D(2) DOPAMINE RECEPTOR
Common Name
English  
DRD2L
Common Name
English  
DRD2
Common Name
English  
DOPAMINE D2 RECEPTOR
Common Name
English  
D2R
Common Name
English  
D2(LONG)
Common Name
English  
Code System Code Type Description Access References
FDA UNII
19GBD6T9L7
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
PRIMARY
PHAROS
P14416
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
PRIMARY
UNIPROT
P14416
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
PRIMARY
From To
1_107 1_182
1_399 1_401
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_5
N 1_17
N 1_23
Related Record Type Details Access References
RADIOLIGAND->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
ANTAGONIST->TARGET
Mediator Substance Details
none
BINDING
Ki
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
INHIBITOR
Ki
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
ANTAGONIST
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
LIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
INHIBITOR
Ki
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
cell:CHO K1; ligand:3H-spiperone
Ki
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
D2R concentration levels were significantly lower in AD patients than in healthy controls (SMD = ?1.13, 95%CI: ?1.52 to ?0.74), with low heterogeneity (I2 = 7.80%), when USA studies were considered.
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
MAJOR
Ki
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
D2S Primary receptor interaction.. Emax 79%
EC50
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
PARTIAL AGONIST->TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
PARTIAL AGONIST
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
ANTAGONIST->TARGET
Mediator Substance Details
none
SELECTIVE
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
RADIOLIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
ANTAGONIST
Created by admin on Wed Aug 04 07:40:48 EDT 2021 , Edited by admin on Wed Aug 04 07:40:48 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:11 EDT 2021 , Edited by admin on Wed Aug 04 01:52:11 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:12 EDT 2021 , Edited by admin on Wed Aug 04 01:52:12 EDT 2021
Name Property Type Amount Referenced Substance Defining Parameters Access References
Molecular Formula CHEMICAL
0
MOL_WEIGHT CHEMICAL
0
Created Wed Aug 04 01:52:11 EDT 2021
Created By admin
Last Edited Wed Aug 04 01:52:11 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 Palacios, J. M., D. L. Niehoff, and M. J. Kuhar. "[3H] Spiperone binding sites in brain: autoradiographic localization of multiple receptors." Brain research 213.2 (1981): 277-289. JA
2 WEBSITE WEBSITE NOMEN PUBLIC_DOMAIN_RELEASE
3 SRS import [19GBD6T9L7] SRS NOMEN Fri Apr 28 15:31:15 EDT 2017
4 Prakash, Chandra, et al. "Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers." Drug metabolism and disposition 26.5 (1998): 448-456. JA PUBLIC_DOMAIN_RELEASE
5 https://en.wikipedia.org/wiki/Raclopride WIKI NOMEN PUBLIC_DOMAIN_RELEASE
6 http://www.uniprot.org/uniprot/P14416?sort=score SRS NOMEN
7 Generated from relationship on:'ONC-201' SYSTEM
8 SRS import [4X6E73CJ0Q] SRS NOMEN Fri Apr 28 14:36:05 EDT 2017
9 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
10 P122 INN
11 Feng, Meihua Rose, Joseph Loo, and Jonathan Wright. "Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome p450 2D6 extensive metabolizers: Species comparison and allometric scaling." Drug metabolism and disposition 26.10 (1998): 982-988. JA PUBLIC_DOMAIN_RELEASE
12 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 01:52:11 EDT 2021
13 Megens, A. A., et al. "Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598)." Journal of Pharmacology and Experimental Therapeutics 260.1 (1992): 146-159. JA
14 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022117s000lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
15 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000PharmR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
16 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
17 P122 INN
18 Jaquet, P., et al. "BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide." Journal of endocrinological investigation 28.11 Suppl International (2005): 21. JA POT
19 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
20 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-264_Apokyn_Pharmr_P2.pdf NDA PUBLIC REVIEW
21 SRS CODE IMPORT SRS NOMEN Fri Apr 28 15:31:15 EDT 2017
22 Jaquet, P., et al. "BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide." Journal of endocrinological investigation 28.11 Suppl International (2005): 21. JA POT
23 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
24 Dopamine Receptor D2 (long isoform) (D2L) WEB PAGE
25 https://pubchem.ncbi.nlm.nih.gov/compound/Metopimazine#section=Biological-Test-Results PUBCHEM POT
26 http://www.uniprot.org/uniprot/P14416 SRS NOMEN PUBLIC_DOMAIN_RELEASE AUTO_SELECTED
27 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
28 Kaur, Sunpreet, et al. "Pharmacology of Dopamine and Its Receptors." Frontiers in Pharmacology of Neurotransmitters. Springer, Singapore, 2020. 143-182. JA
29 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
30 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
31 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
32 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
33 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
34 https://www.drugbank.ca/drugs/DB06216 WEBSITE
35 WIKI WIKI PUBLIC_DOMAIN_RELEASE
36 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
37 https://www.drugbank.ca/drugs/DB00714#BE0000581 WEBSITE
38 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
39 http://oncoceutics.com/onc201-clinical-trial-results-accepted-2016-asco-poster-discussion-session/ WEBSITE NOMEN
40 Pan, Xiongfeng, et al. "Dopamine and dopamine receptors in Alzheimer’s disease: a systematic review and network meta-analysis." Frontiers in aging neuroscience 11 (2019): 175. JA
41 UNIPROT UNIPROT NOMEN

Version

Version Comments

Editor

Change Date

161
admin
Wed Aug 04 03:40:48 EDT 2021